Aripiprazole Tablet
Product Images NDC 50090-7564

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-7564). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Aripiprazole Fig1)

This text is about the effect of other drugs on Aripiprazole. It mentions different drugs like CYP3A4 inhibitors (Ketoconazole), CYP2D6 inhibitors (Quinidine), CYP induction agents (Carbamazepine), Gastric Acid Blockers (Famotidine), and others like Valproate and Lorazepam. The text also shows a graph indicating the fold change and 90% CI of Aripiprazole relative to the reference levels without the interacting drugs.*

FDA Label Image

Figure (Aripiprazole Fig2)

This text discusses the effects of various drugs on Aripiprazole metabolism. It mentions specific inhibitors and inductors of enzymes such as CYP3A4, CYP2D6, and CYP3AA. Additionally, it includes the influence of gastric acid blockers and other medications like valproate and lorazepam on Aripiprazole. The text also presents data on Dehydro-Aripiprazole Fold Change and different measurements such as AUC, Cmax, and their relative changes compared to the reference levels.*

FDA Label Image

Figure (Aripiprazole Fig3)

This information is discussing the effect of Aripiprazole on other drugs. It includes data on fold change and 90% CI for various drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, and desmethylvenlafaxine. The text provides insights into changes relative to a reference state without interacting drugs.*

FDA Label Image

Figure (Aripiprazole Fig4)

FDA Label Image

Figure (Aripiprazole Fig5)

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

This is a table showing the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a study comparing aripiprazole and placebo in schizophrenia treatment. The table includes the proportion of patients with relapse over time, the number of subjects at risk in each group, and the days from randomization. The data suggests Aripiprazole may have a lower relapse rate compared to the placebo.*

FDA Label Image

Figure 9: Least Square Means Of Change From Baseline In Ygtss Tts By Week (tourette’s Disorder Study 1) (Aripiprazole Fig7)

This text provides information about the least-squares mean change in the YGTSS Total TIC Score over different weeks of treatment with Aripiprazole (low and high doses) and Placebo. The data shows the change in YGTSS Total TIC Score from baseline.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

FDA Label Image

Label Image (Lbl500907564)

This appears to be a label for Aripiprazole, a medication usually prescribed to treat certain mental/mood disorders. The label specifies the product number 7372-0 and indicates the dosage of 2mg per tablet. It suggests storing the tablets at a temperature of 8-10 degrees Celsius. The package contains 30 tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.